RxDoctor Payments Data

Kelly Storrs, NP

Family · Whitney Point, NYNPI 1932187374

Payments from drug & device makers

$572in general payments, 2019–2025

Across 20 payments — averaging $28.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$228
  • Otsuka America Pharmaceutical, Inc.$141
  • Acadia Pharmaceuticals Inc$132
  • Lilly USA, LLC$48
  • Avanir Pharmaceuticals, Inc.$24

What the payments were for

  • Food & beverage$46181%
  • Education$11119%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$572 in reported general payments places this provider in the 60th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$163,652
Medicare patients
406
Services billed
2,082

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban524$154,129
NuplazidPimavanserin Tartrate16$31,375
XifaxanRifaximin22$30,898
TrulicityDulaglutide29$25,198
JanuviaSitagliptin Phosphate78$24,272
JardianceEmpagliflozin71$21,728
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$20,124
FarxigaDapagliflozin Propanediol64$18,602
Breo ElliptaFluticasone/Vilanterol40$17,572
XareltoRivaroxaban53$16,250
Tresiba Flextouch U-100Insulin Degludec98$10,932
EntrestoSacubitril/Valsartan41$10,154
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog31$9,495
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog117$9,344
CombiganBrimonidine Tartrate/Timolol34$8,674

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$132$31,37516 claims
Lilly USA, LLCTrulicity$48$25,19829 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,883 family providers in New York.

Other family in Whitney Point

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →